NasdaqGS:BRKRLife Sciences
Bruker (BRKR) Could Be 6% Undervalued After Quarterly Loss And 2026 Guidance
Why Bruker stock is back in focus after the latest quarterly update
Bruker (BRKR) is back on investors’ radar after second quarter results combined rising sales with a reported net loss driven largely by impairment charges. Fresh 2026 revenue guidance added another key data point for the stock.
See our latest analysis for Bruker.
Bruker’s latest guidance for 2026, combined with the second quarter impairment charges, has come alongside a 25.91% 90 day share price return and an 83.88% 1 year...